Edwards Lifesciences Corp. (EW)

$69.6

+0.42

(+0.61%)▲

Market is closed - opens 7 PM, 04 Oct 2023

Performance

  • $69.00
    $70.15
    $69.60
    downward going graph

    0.86%

    Downside

    Day's Volatility :1.64%

    Upside

    0.78%

    downward going graph
  • $67.13
    $94.87
    $69.60
    downward going graph

    3.55%

    Downside

    52 Weeks Volatility :29.24%

    Upside

    26.64%

    downward going graph

Returns

PeriodEdwards Lifesciences Corp.
3 Months
-24.39%
6 Months
-16.85%
1 Year
-19.05%
3 Years
-13.69%

Highlights

Market Capitalization
42.1B
Book Value
$10.49
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
2.24
PE Ratio
30.88
PEG Ratio
3.07
Wall Street Target Price
96.74
Profit Margin
24.56%
Operating Margin TTM
28.44%
Return On Assets TTM
11.54%
Return On Equity TTM
22.4%
Revenue TTM
5.7B
Revenue Per Share TTM
9.25
Quarterly Revenue Growth YOY
11.4%
Gross Profit TTM
4.3B
EBITDA
1.8B
Diluted Eps TTM
2.24
Quarterly Earnings Growth YOY
-0.23
EPS Estimate Current Year
2.55
EPS Estimate Next Year
2.88
EPS Estimate Current Quarter
0.65
EPS Estimate Next Quarter
0.63

Analyst Recommendation

Buy
    59%Buy
    37%Hold
    2%Sell
Based on 37 Wall street analysts offering stock ratings for Edwards Lifesciences Corp.(by analysts ranked 0 to 5 stars)
Based on 37 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
22
22
22
Hold
14
14
14
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 38.99%

Current $69.60
Target $96.74

Company Financials

FY17Y/Y Change
Revenue
3.4B
↑ 15.91%
Net Income
583.6M
↑ 2.48%
Net Profit Margin
16.99%
↓ 2.23%
FY18Y/Y Change
Revenue
3.7B
↑ 8.37%
Net Income
722.2M
↑ 23.75%
Net Profit Margin
19.4%
↑ 2.41%
FY19Y/Y Change
Revenue
4.3B
↑ 16.79%
Net Income
1.0B
↑ 44.96%
Net Profit Margin
24.08%
↑ 4.68%
FY20Y/Y Change
Revenue
4.4B
↑ 0.88%
Net Income
823.4M
↓ 21.35%
Net Profit Margin
18.77%
↓ 5.31%
FY21Y/Y Change
Revenue
5.2B
↑ 19.29%
Net Income
1.5B
↑ 82.55%
Net Profit Margin
28.73%
↑ 9.96%
FY22Y/Y Change
Revenue
5.4B
↑ 2.86%
Net Income
1.5B
↑ 1.25%
Net Profit Margin
28.28%
↓ 0.45%
Q1 FY22Q/Q Change
Revenue
1.3B
↑ 0.86%
Net Income
373.6M
↑ 11.42%
Net Profit Margin
27.86%
↑ 2.64%
Q2 FY22Q/Q Change
Revenue
1.4B
↑ 2.44%
Net Income
406.4M
↑ 8.78%
Net Profit Margin
29.58%
↑ 1.72%
Q3 FY22Q/Q Change
Revenue
1.3B
↓ 4.0%
Net Income
343.5M
↓ 15.48%
Net Profit Margin
26.04%
↓ 3.54%
Q4 FY22Q/Q Change
Revenue
1.3B
↑ 2.22%
Net Income
398.4M
↑ 15.98%
Net Profit Margin
29.55%
↑ 3.51%
Q1 FY23Q/Q Change
Revenue
1.5B
↑ 8.25%
Net Income
340.5M
↓ 14.53%
Net Profit Margin
23.33%
↓ 6.22%
Q2 FY23Q/Q Change
Revenue
1.5B
↑ 4.84%
Net Income
305.5M
↓ 10.28%
Net Profit Margin
19.96%
↓ 3.37%
FY17Y/Y Change
Total Assets
5.7B
↑ 26.29%
Total Liabilities
2.7B
↑ 44.88%
FY18Y/Y Change
Total Assets
5.3B
↓ 6.53%
Total Liabilities
2.2B
↓ 20.31%
FY19Y/Y Change
Total Assets
6.5B
↑ 21.87%
Total Liabilities
2.3B
↑ 7.17%
FY20Y/Y Change
Total Assets
7.2B
↑ 11.54%
Total Liabilities
2.7B
↑ 13.8%
FY21Y/Y Change
Total Assets
8.5B
↑ 17.49%
Total Liabilities
2.7B
↑ 0.15%
FY22Y/Y Change
Total Assets
8.3B
↓ 2.47%
Total Liabilities
2.5B
↓ 6.78%
Q1 FY22Q/Q Change
Total Assets
8.4B
↓ 0.97%
Total Liabilities
2.6B
↓ 3.44%
Q2 FY22Q/Q Change
Total Assets
8.4B
↑ 0.06%
Total Liabilities
2.5B
↓ 3.63%
Q3 FY22Q/Q Change
Total Assets
8.6B
↑ 2.53%
Total Liabilities
2.4B
↓ 2.46%
Q4 FY22Q/Q Change
Total Assets
8.3B
↓ 4.0%
Total Liabilities
2.5B
↑ 2.7%
Q1 FY23Q/Q Change
Total Assets
8.7B
↑ 4.33%
Total Liabilities
2.6B
↑ 4.16%
Q2 FY23Q/Q Change
Total Assets
9.0B
↑ 4.08%
Total Liabilities
2.6B
↓ 1.22%
FY17Y/Y Change
Operating Cash Flow
1.0B
↑ 42.06%
Investing Cash Flow
-647.2M
↑ 205.72%
Financing Cash Flow
-473.2M
↑ 76.24%
FY18Y/Y Change
Operating Cash Flow
926.8M
↓ 7.38%
Investing Cash Flow
76.7M
↓ 111.85%
Financing Cash Flow
-1.1B
↑ 132.71%
FY19Y/Y Change
Operating Cash Flow
1.2B
↑ 27.26%
Investing Cash Flow
-595.8M
↓ 876.79%
Financing Cash Flow
-115.6M
↓ 89.5%
FY20Y/Y Change
Operating Cash Flow
1.1B
↓ 10.61%
Investing Cash Flow
-531.1M
↓ 10.86%
Financing Cash Flow
-486.9M
↑ 321.19%
FY21Y/Y Change
Operating Cash Flow
1.7B
↑ 64.29%
Investing Cash Flow
-1.7B
↑ 224.33%
Financing Cash Flow
-356.3M
↓ 26.82%
Q1 FY22Q/Q Change
Operating Cash Flow
293.3M
↓ 21.49%
Investing Cash Flow
229.5M
↓ 123.76%
Financing Cash Flow
-368.1M
↑ 493.71%
Q2 FY22Q/Q Change
Operating Cash Flow
332.2M
↑ 13.26%
Investing Cash Flow
129.6M
↓ 43.53%
Financing Cash Flow
-308.1M
↓ 16.3%
Q3 FY22Q/Q Change
Operating Cash Flow
309.9M
↓ 6.71%
Investing Cash Flow
-201.5M
↓ 255.48%
Financing Cash Flow
-69.9M
↓ 77.31%
Q1 FY23Q/Q Change
Operating Cash Flow
314.1M
↑ 11.07%
Investing Cash Flow
500.0K
-
Financing Cash Flow
-206.6M
↓ 75.36%

Technicals Summary

Sell

Neutral

Buy

Edwards Lifesciences Corp. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-8.94%
-16.85%
-19.05%
-13.69%
33.26%
Stryker Corporation
Stryker Corporation
-7.13%
-7.39%
26.9%
27.93%
57.77%
Boston Scientific Corp.
Boston Scientific Corp.
-3.3%
2.94%
28.71%
34.58%
38.97%
Abbott Laboratories
Abbott Laboratories
-5.11%
-6.88%
-7.13%
-11.82%
33.29%
Medtronic Plc
Medtronic Plc
-3.03%
-2.14%
-7.96%
-25.01%
-19.81%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
30.93
30.93
3.07
2.55
0.22
0.12
0.0
10.49
Stryker Corporation
Stryker Corporation
38.68
38.68
2.85
10.36
0.16
0.06
0.01
45.71
Boston Scientific Corp.
Boston Scientific Corp.
89.49
89.49
2.53
2.0
0.05
0.04
0.0
12.46
Abbott Laboratories
Abbott Laboratories
33.05
33.05
18.76
4.39
0.14
0.06
0.02
21.42
Medtronic Plc
Medtronic Plc
28.92
28.92
3.04
5.28
0.07
0.04
0.04
38.47
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$42.1B
33.26%
30.93
24.56%
Stryker Corporation
Stryker Corporation
Buy
$104.0B
57.77%
38.68
13.92%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$77.3B
38.97%
89.49
6.81%
Abbott Laboratories
Abbott Laboratories
Buy
$168.1B
33.29%
33.05
12.83%
Medtronic Plc
Medtronic Plc
Buy
$104.3B
-19.81%
28.92
11.47%

Institutional Holdings

  • Vanguard Group Inc

    8.44%

  • BlackRock Inc

    8.36%

  • State Street Corporation

    4.45%

  • Capital Research & Mgmt Co - Division 3

    4.44%

  • AllianceBernstein L.P.

    3.37%

  • Bank of New York Mellon Corp

    2.91%

Company Information

edwards lifesciences (nyse: ew) is the global leader in the science of heart valves and hemodynamic monitoring. driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that save and enhance lives. headquartered in irvine, california, edwards lifesciences has extensive operations in north america, europe, japan, latin america and asia and currently employs about 6,400 individuals worldwide. for us, helping patients is not a slogan – it's our life’s work. from developing devices that replace or repair a diseased heart valve to creating new technologies that monitor vital signs in the critical care setting, we help ensure that patients regain and even improve their quality of life.

Organization
Edwards Lifesciences Corp.
Employees
17300
CEO
Mr. Michael A. Mussallem
Industry
Health Technology

Discover More

FAQs